## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.01 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($323.46)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Is Now the Right Time to Revisit Amgen After Its Recent 18% Price Surge?**
- Source: Simply Wall Street | 20251130T042057 | Bullish | Relevance: 100%
- Amgen's stock has surged 18% in the last month, prompting a re-evaluation of its current valuation. A Discounted Cash Flow (DCF) analysis suggests Amgen (NASDAQ:AMGN) may be undervalued by 37.8%, with an intrinsic value of $555.10 per share. The article also discusses Amgen's PE ratio of 26.6x, which is above the industry average but below its peer group, and introduces "Narratives" as a tool for investors to customize their valuation outlook based on different scenarios for Amgen's future.

**2. Edgestream Partners L.P. Buys 12,318 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251202T094630 | Bullish | Relevance: 100%
- Edgestream Partners L.P. increased its stake in Amgen Inc. by 86.4% in the second quarter, now owning 26,572 shares valued at $7.419 million. Other institutional investors like Vanguard Group Inc., Geode Capital Management LLC, and Charles Schwab Investment Management Inc. also modified their holdings. Analysts have updated price targets for Amgen, with the stock currently holding an average "Hold" rating and a consensus price target of $333.74.

**3. Railway Pension Investments Ltd Has $24.60 Million Holdings in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251130T125017 | Somewhat-Bullish | Relevance: 99%
- Railway Pension Investments Ltd increased its stake in Amgen Inc. by 28.2% in the second quarter, bringing its total holdings to $24.60 million. Other institutional investors like Laurel Wealth Advisors LLC, Norges Bank, and Vanguard Group Inc. also significantly adjusted their positions in Amgen. Wall Street analysts currently have a "Hold" consensus rating for Amgen with a target price of $333.74, and the company recently announced a quarterly dividend.

**4. Beacon Pointe Advisors LLC Sells 4,768 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251202T084752 | Somewhat-Bullish | Relevance: 99%
- Beacon Pointe Advisors LLC reduced its stake in Amgen Inc. by 5.1% during the second quarter, selling 4,768 shares but still owning 87,981 shares valued at $24.565 million. Amgen reported strong quarterly earnings, beating expectations with $5.64 EPS and $9.56 billion in revenue, and set an optimistic FY2025 EPS guidance. The company also declared a quarterly dividend of $2.38, while institutional investors hold a significant 76.5% of its stock.

**5. Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow**
- Source: Amgen | 20251202T130322 | Bullish | Relevance: 99%
- Amgen is leveraging artificial intelligence (AI), automation, and biology through its generative biology platform to design next-generation medicines. The company's AMPLIFY protein language model, co-developed with Mila, teaches AI the language of proteins to accelerate protein engineering and drug discovery. This approach, which includes a "design → make → test → learn" generative loop, has tripled protein engineering speed and cut discovery timelines by half, aiming for more precise, effective, and predictable medicines.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |
| 2025-11-14 | Piper Sandler | $381 | $342 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |
| 2025-11-14 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Forward P/E 15.5x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (3 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $169.8B |
| Beta | 0.45 |
| 52W Range | $253.30 - $346.38 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 15.5 |
| Current P/E | 15.9 |
| YoY Growth | 2.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.7% to -0.1% (-5.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.1pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.00), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.12% (CS: 59) | Neutral |
| RSI_14 | 61.9 | Neutral |
| MACD Histogram | -1.00 | Bearish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.097x | Above |
| vs SMA200 | 1.143x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $338.36
- **Stop Loss:** $323.46 (4.4% risk)
- **Target:** $368.16 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 67
- **Position Value:** $22,670.12
- **Portfolio %:** 22.67%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*